Table 2.
Variables | RDW + NLR = 0, n (%) | RDW + NLR = 1, n (%) | RDW + NLR = 2, n (%) | P |
---|---|---|---|---|
Age | 0.041 | |||
≤54 | 24 (23.3%) | 20 (19.4%) | 9 (8.7%) | |
>54 | 14 (13.6%) | 17 (16.5%) | 19 (18.4%) | |
Gender | 0.565 | |||
Female | 13 (12.6%) | 16 (15.5%) | 13 (12.6%) | |
Male | 25 (24.3%) | 21 (20.4%) | 15 (14.6%) | |
Tumor location | 0.014 | |||
Pyloric antrum | 22 (21.4%) | 21 (20.4%) | 7 (6.8%) | |
Nonpyloric antrum | 16 (15.5%) | 16 (15.5%) | 21 (20.4%) | |
HER-2 | 0.867 | |||
Positive | 11 (10.7%) | 11 (10.7%) | 6 (5.8%) | |
Negative | 20 (19.4%) | 15 (14.6%) | 10 (9.7%) | |
Unknown | 7 (6.8%) | 11 (10.7%) | 12 (11.7%) | |
TNM stage | 0.007 | |||
I-II | 11 (10.7%) | 8 (7.8%) | 1 (1.0%) | |
III | 13 (12.6%) | 8 (7.8%) | 4 (3.9%) | |
IV | 14 (13.6%) | 21 (20.4%) | 23 (22.3%) | |
Metastasis | 0.001 | |||
Yes | 14 (13.6%) | 21 (20.4%) | 23 (22.3%) | |
No | 24 (23.3%) | 16 (15.5%) | 5 (4.9%) | |
RDW (%) | <0.001 | |||
≤13.4% | 38 (36.9%) | 15 (14.6%) | 0 (0.0%) | |
>13.4% | 0 (0.0%) | 22 (21.4%) | 28 (27.2%) | |
WBC (g/L) | 0.001 | |||
≤5.69 | 22 (21.4%) | 21 (20.4%) | 9 (8.7%) | |
>5.69 | 16 (15.5%) | 16 (15.5%) | 19 (18.4%) | |
MO (g/L) | 0.830 | |||
≤0.42 | 21 (20.4%) | 23 (22.3%) | 9 (8.7%) | |
>0.42 | 17 (16.5%) | 14 (13.6%) | 19 (18.4%) | |
NLR | <0.001 | |||
≤2.755 | 38 (36.9%) | 22 (21.4%) | 0 (0.0%) | |
>2.755 | 0 (0.0%) | 15 (14.6%) | 28 (27.2%) | |
CA125 (U/mL) | 0.022 | |||
≤26.6 | 23 (22.3%) | 22 (22.3%) | 11 (10.7%) | |
>26.6 | 15 (14.6%) | 15 (14.6%) | 17 (16.5%) | |
CA199 (U/mL) | 0.042 | |||
≤11.9 | 23 (22.3%) | 19 (18.4%) | 14 (13.6%) | |
>11.9 | 15 (14.6%) | 18 (17.5%) | 14 (13.6%) | |
CEA (μg/L) | 0.190 | |||
≤2.4 | 21 (20.4%) | 22 (21.4%) | 11 (10.7%) | |
>2.4 | 17 (16.5%) | 15 (14.6%) | 17 (16.5%) |
RDW + NLR: combination of red blood cell distribution width and neutrophil-to-lymphocyte ratio; RDW: red cell distribution width; MO: monocyte; NLR: neutrophil-to-lymphocyte ratio. P less than 0.05 is statistically significant.